Partnership Opportunities
Investment into CKD has never been greater, and as large pharma and emerging biotech companies continue to expand their renal pipelines, the need for greater patient diversity across clinical trials, sophisticated biomarker screens to stratify best responders to SGLT2s, and robust models recapitulating the complex pathophysiology of specific forms of CKD become greater and greater. The 6th CKD Drug Development Summit presented a timely and unrivalled opportunity for your company to stay ahead of the curve and position yourself at the forefront of the minds of highly engaged experts prioritizing rare and chronic kidney diseases.
Download the event guide to learn more about how you could have showcased your brand and capitalized on our audience of leading companies with active pipelines in CKD, IgAN, Lupus Nephritis, FSGS, CG3 and other cardiorenal indications.
Why Partner Next Year:
Secure an exhibition booth to present and position your capabilities to developers who are actively seeking new solutions to optimize drug development inefficiencies.
Network one-to-one with stakeholders during our coordinated networking sessions to first-hand understand their requirements and present your solution.
Deliver a presentation and influence the thinking of preclinical, translational, and clinical decision makers working to identify new promising compounds and drive success in the clinic.
Our 2024 Partners
Regeneron, Eli Lilly, Novo Nordisk, Novartis, GSK and AstraZeneca were amongst our other 200+ attendees that were seeking partners to help them in the following areas:
Contract Research – accelerate and support preclinical and clinical R&D and position yourself as the leading CRO in rare and common kidney disorders
Non-Invasive Biomarkers – communicate your capabilities to enhance the development and validation of fluid and imaging biomarkers to detect CKD at an earlier stage and more precisely monitor renal function
Preclinical Models – showcase your expertise in developing translatable, validated in vivo or in vitro models that reliably predict how drugs interact within human kidney tissue